Logo image of RZLT

REZOLUTE INC (RZLT) Stock Fundamental Analysis

USA - NASDAQ:RZLT - US76200L3096 - Common Stock

8.5301 USD
-0.28 (-3.18%)
Last: 9/25/2025, 2:08:09 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RZLT. RZLT was compared to 538 industry peers in the Biotechnology industry. While RZLT has a great health rating, there are worries on its profitability. RZLT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RZLT has reported negative net income.
In the past year RZLT has reported a negative cash flow from operations.
In the past 5 years RZLT always reported negative net income.
In the past 5 years RZLT always reported negative operating cash flow.
RZLT Yearly Net Income VS EBIT VS OCF VS FCFRZLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

RZLT's Return On Assets of -42.40% is in line compared to the rest of the industry. RZLT outperforms 56.32% of its industry peers.
RZLT has a Return On Equity of -45.90%. This is in the better half of the industry: RZLT outperforms 67.84% of its industry peers.
Industry RankSector Rank
ROA -42.4%
ROE -45.9%
ROIC N/A
ROA(3y)-45.28%
ROA(5y)-42.37%
ROE(3y)-49.01%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
RZLT Yearly ROA, ROE, ROICRZLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RZLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RZLT Yearly Profit, Operating, Gross MarginsRZLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

RZLT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RZLT has more shares outstanding
RZLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RZLT Yearly Shares OutstandingRZLT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
RZLT Yearly Total Debt VS Total AssetsRZLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

RZLT has an Altman-Z score of 30.70. This indicates that RZLT is financially healthy and has little risk of bankruptcy at the moment.
RZLT has a better Altman-Z score (30.70) than 95.72% of its industry peers.
RZLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 30.7
ROIC/WACCN/A
WACCN/A
RZLT Yearly LT Debt VS Equity VS FCFRZLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

2.3 Liquidity

RZLT has a Current Ratio of 14.37. This indicates that RZLT is financially healthy and has no problem in meeting its short term obligations.
RZLT's Current ratio of 14.37 is amongst the best of the industry. RZLT outperforms 88.66% of its industry peers.
A Quick Ratio of 14.37 indicates that RZLT has no problem at all paying its short term obligations.
RZLT has a better Quick ratio (14.37) than 88.85% of its industry peers.
Industry RankSector Rank
Current Ratio 14.37
Quick Ratio 14.37
RZLT Yearly Current Assets VS Current LiabilitesRZLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

RZLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.07%, which is quite impressive.
EPS 1Y (TTM)27.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RZLT will show a very strong growth in Earnings Per Share. The EPS will grow by 27.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y4.39%
EPS Next 3Y24.34%
EPS Next 5Y27.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RZLT Yearly Revenue VS EstimatesRZLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
RZLT Yearly EPS VS EstimatesRZLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RZLT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RZLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RZLT Price Earnings VS Forward Price EarningsRZLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RZLT Per share dataRZLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

RZLT's earnings are expected to grow with 24.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.39%
EPS Next 3Y24.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RZLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REZOLUTE INC

NASDAQ:RZLT (9/25/2025, 2:08:09 PM)

8.5301

-0.28 (-3.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-17 2025-09-17/amc
Earnings (Next)11-05 2025-11-05
Inst Owners52.04%
Inst Owner Change71.95%
Ins Owners1.41%
Ins Owner Change0.16%
Market Cap740.50M
Analysts86.25
Price Target13.6 (59.44%)
Short Float %9.47%
Short Ratio8.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.08%
Min EPS beat(2)-18.3%
Max EPS beat(2)-15.86%
EPS beat(4)2
Avg EPS beat(4)3.16%
Min EPS beat(4)-18.3%
Max EPS beat(4)34.64%
EPS beat(8)4
Avg EPS beat(8)-1.73%
EPS beat(12)8
Avg EPS beat(12)7.48%
EPS beat(16)10
Avg EPS beat(16)7.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.69%
PT rev (3m)0.63%
EPS NQ rev (1m)1.98%
EPS NQ rev (3m)-1.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.57
P/tB 4.57
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS1.87
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.4%
ROE -45.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.28%
ROA(5y)-42.37%
ROE(3y)-49.01%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.37
Quick Ratio 14.37
Altman-Z 30.7
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.91%
EPS Next Y-6.84%
EPS Next 2Y4.39%
EPS Next 3Y24.34%
EPS Next 5Y27.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-13.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.41%
OCF growth 3YN/A
OCF growth 5YN/A